Patents by Inventor Alpana Waldron

Alpana Waldron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Correlation of molecular markers with clinical outcome in GBM patients radiation treated with or without gefitinib
    Patent number: 8557527
    Abstract: Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: October 15, 2013
    Assignees: HistoRx, Inc., Radiation Therapy Oncology Group of the American College of Radiology
    Inventors: Arnab Chakravarti, Robert Pinard, Agnes Ang, Marisa P. Dolled-Filhart, Annette Molinaro, Alpana Waldron
  • ASSOCIATION OF BIOMARKERS WITH PATIENT OUTCOME
    Publication number: 20120270233
    Abstract: The present method relates to quantification of prognostic and predictive biomarkers of the PDK/AKT/mTOR pathway, such as GSK3?, S6, CREB, PTEN, AKT and mTOR, using AQUA® analysis to estimate both patient risk and benefit of treatment to patients diagnosed with glioblastoma. Unlike traditional IHC, the AQUA® system is objective and produces quantitative in situ protein expression data on a continuous scale. Taking advantage of the power of the AQUA system, the present method provides a highly robust and standardized diagnostic assays that can be used in the clinical setting to provide physicians with reliable prognostic and predictive information. Glioblastoma multiform (GBM) remains one of the most aggressive human cancers, and biomarkers that provide prognostic and predictive information would be extremely valuable to both the physician and the patient. A patient's risk may be determined using the prognostic biomarkers of the present method.
    Type: Application
    Filed: February 10, 2009
    Publication date: October 25, 2012
    Inventors: Donald E. Waldron, Alpana Waldron, Robert Pinard, Mark Gustavson
  • CORRELATION OF MOLECULAR MARKERS WITH CLINICAL OUTCOME IN GBM PATIENTS RADIATION TREATED WITH OR WITHOUT GEFITINIB
    Publication number: 20100144540
    Abstract: Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers.
    Type: Application
    Filed: September 22, 2009
    Publication date: June 10, 2010
    Inventors: Arnab Chakravarti, Robert Pinard, Donald Waldron, Agnes Ang, Marisa P. Dolled-Filhart, Annette Molinaro, Alpana Waldron
  • SRC ACTIVATION FOR DETERMINING CANCER PROGNOSIS AND AS A TARGET FOR CANCER THERAPY
    Publication number: 20100081666
    Abstract: Methods of cancer diagnosis and prognosis using biomarkers.
    Type: Application
    Filed: July 14, 2009
    Publication date: April 1, 2010
    Applicant: Wyeth
    Inventors: Christina M. COUGHLIN, Michael E. BURCZYNSKI, Marisa P. DOLLED-FILHART, Robert PINARD, Donald WALDROM, Charles ZACHARCHUK, Frederick IMMERMANN, Maha KARNOUB, Jason CHRISTIANSEN, Mark GUSTAVSON, Annette MOLINARO, Alpana Waldron